Data of safety in a single-center alemtuzumab treated population

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach.In the m...

Full description

Bibliographic Details
Main Authors: Maria di Ioia, Vincenzo Di Stefano, Deborah Farina, Valeria Di Tommaso, Daniela Travaglini, Erika Pietrolongo, Stefano L. Sensi, Marco Onofrj, Giovanna De Luca
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:Data in Brief
Online Access:http://www.sciencedirect.com/science/article/pii/S2352340920302353